An error occurred retrieving publication content to display, please try again.
Page not found (404)
Sorry - the page you requested could not be found.
Please choose a page from the navigation or try a website search above to find the information you need.
Toolkit
Study found that treatment with recombinant human growth hormone gave significantly greater benefits in stature for children with growth hormone deficiency (GHD), Turner syndrome, Prader–Willi syndrome, chronic renal insufficency, short stature homeobox-containing gene deficiency, and those who were small for gestational age, than for untreated children. However, treatment was considered to be cost-effective at a willingness to pay threshold of £20,000–30,000 per quality-adjusted life-year gained only for children with GHD, although the analysis is subject to a range of important uncertainties
Southampton Health Technology Assessments Centre (SHTAC), Southampton, UK
* Corresponding author Email: j.s.bryant@soton.ac.uk
Funding: {{metadata.Funding}}
{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}
https://doi.org/{{metadata.DOI}}
Citation:{{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al. ' : ''}}. {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})
Report Content
The full text of this issue is available as a PDF document from the Toolkit section on this page.
The full text of this issue is available as a PDF document from the Toolkit section on this page.
Responses to this report
No responses have been published.
An error has occurred in processing the XML document